In vitro studies have shown that in most ESCC cells, the mTOR pathway is abnormally activated, and everolimus alone or in combination with cisplatin exerted a therapeutic influence on these cells.75 This evidence concerns the gene MTOR and esophageal squamous cell carcinoma.